Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 6/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | PTPRB | P23467 | 9/20 | 0.34 |
| ▸ | BACE1 | P56817 | 3/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28064131 | 1.00 | ABCB1 (0.52) | ABCB1CA1CA2CA7CA4 | |
| SCHEMBL24140420 | 0.93 | ABCB1 (0.62) | ABCB1CA1CA2CA7PTPRB | |
| SCHEMBL15433017 | 0.86 | ABCB1 (0.53) | ABCB1CA1CA2CA7CA4 | |
| SCHEMBL15236993 | 0.86 | ABCB1 (0.53) | ABCB1CA1CA2CA7CA4 | |
| SCHEMBL18928619 | 0.86 | ABCB1 (0.53) | ABCB1CA1CA2CA7CA4 | |
| SCHEMBL13108147 | 0.84 | ABCB1 (0.54) | ABCB1CA1CA2CA7CA4 | |
| SCHEMBL18928362 | 0.84 | ABCB1 (0.54) | ABCB1CA1CA2CA7CA4 | |
| SCHEMBL15432495 | 0.84 | ABCB1 (0.54) | ABCB1CA1CA2CA7CA4 | |
| SCHEMBL28634475 | 0.82 | ABCB1 (0.38) | ABCB1CA2PTPRB | |
| SCHEMBL28634476 | 0.82 | ABCB1 (0.38) | ABCB1CA2PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12144864-B2 | Tubulysins and protein-tubulysin conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| CN-113454097-A | Tubulysins and protein-tubulysin conjugates | 里珍纳龙药品有限公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-103333133-B | The synthetic method of a kind of Tubulysin family compound key intermediate TUV | 西北师范大学 | 2016-06-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12144864-B2 | Tubulysins and protein-tubulysin conjugates | SDCBP, TEK, TEKT1 | ABCB1 895/4885CA1 3635/4885CA2 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.